Challenging Cases: When and How to Use GLP-1 Agonists in Diabetes Management- CEU 2019 Enduring

Challenging Cases: When and How to Use GLP-1 Agonists in Diabetes Management- CEU 2019 Enduring
This course was a live CME-certified Ancillary Symposium presented at CEU 2019, held in Seattle, WA. This educational activity is supported by an independent medical educational grant from Novo Nordisk Inc. These ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC).
PLEASE REGISTER THEN CLICK "START" TO:
TAKE PRE-SURVEY
WATCH RECORDING SESSION
EVALUATE SESSION
CLAIM CME
DOWNLOAD PRESENTATION SLIDES
PRINT A CERTIFICATE OF ATTENDANCE OR CERTIFICATE OF PARTICIPATION
Target Audience
This activity is intended for endocrinologists and endocrine fellows, primary care physicians, physician’s assistants, nurse practitioners and other healthcare professionals.
Learning Objectives
Upon completion of this educational activity, learners will be able to:
- Apply guidelines and algorithms on the initiation and treatment of pharmacotherapies for the management of type 2 diabetes.
- Devise individualized initiation and treatment plans for patients with type 2 diabetes that incorporates updated clinical information on GLP-1 agonist options and take into consideration indications, safety, and efficacy as well as diabetes complications or significant risk factors.
Additional Information
Program Co-Chairs
Carol Wysham, MD
Section Head
Rockwood Center
Clinical Associate Professor
University of Washington
Spokane, WA
Marie E. McDonnell, MD
Diabetes Section Chief
Brigham and Women’s Hospital
Harvard University
Boston, MA
DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following patient representative reported no relevant financial relationships during the content development process for this activity: Marie E. McDonnell, MD
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Carol Wysham, MD: Consulting, Astra Zeneca, Abbott, Janssen, Novo Nordisk, Sanofi; Speaker, Astra Zeneca, Boehringer Ingelheim, Janssen, Novo Nordisk, Sanofi; Research, Abbott, Novo Nordisk, Mylan, Lilly
The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships: Beret Ann Casey, MD
The following SPC Committee members reported financial relationships:
Andjela T. Drincic, MD: Advisory Board Member, Corcept
Sergio Fazio, MD, PhD: Consultant, Amarin, Amgen, Esperion, AstraZeneca
Steven T. Harris, MD: Ad hoc consultant on Advisory Boards, Eli Lilly & Company, Radius Health; Speaker, Amgen, Eli Lilly & Company, Radius Health
Jonathan Purnell, MD: Advisor, Novo Nordisk
Amy Rothberg, MD: Advisor, Rhythm Pharmaceuticals; Spouse, consultant of Merck
Susmeeta Sharma, MD: Speaker, Corcept
The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.
The following SPC members reported no relevant financial relationships:
Lorena Alarcon-Casas Wright, MD, Deborah Sellmeyer, MD, Neena Natt, MD, Steven Weitzman, MD
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

MAINTENANCE OF CERTIFICATION
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Review your Diplomate ABIM ID Number(s)
In order to earn and report MOC points to the American Board of Internal Medicine (ABIM), you must:
- Provide your board-certification information in your educational profile. Your profile currently contains the following board ID numbers (must be logged in to view):
Your ABIM Number: [current-user:profile-profile:field-number-abim]*
*If your ABIM number is blank or incorrect as shown above, please click the Update Profile button below to add or correct your profile.
Available Credit
- 1.00 ABIM MOC
- 1.00 AMA PRA Category 1 Credits™
- 1.00 CME Certificate of Participation
- TAKE PRE-SURVEY
- WATCH RECORDING SESSION
- EVALUATE SESSION
- CLAIM CME
- DOWNLOAD PRESENTATION SLIDES
- PRINT A CERTIFICATE OF ATTENDANCE OR CERTIFICATE OF PARTICIPATION